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A B S T R A C T
The etiology and pathogenesis of tumors of the central nervous system are still inadequately explained. In the present
study the expression patterns of a critical molecular component of wnt signaling pathway – axin 1 was investigated in 42
patients with glioblastoma, the most aggressive form of glial tumors. Immunostaining and image analysis revealed the
quantity and localization of the protein. Downregulation of this tumor suppressor expression was observed in 31% of tu-
mors when compared to the levels of axin in healthy brain tissues. Axin was observed in the cytoplasm in 69% of
glioblastoma samples, in 21.4% in both the cytoplasm and nucleus and 9.5% had expression solely in the nucleus. Mean
values of relative axin’s expression obtained by image analysis showed that the highest relative quantity of axin was mea-
sured when the protein was in the nucleus and the lowest relative quantity of axin when the protein was localized in the
cytoplasm. Investigation on axin’s existence at the subcellular level in glioblastomas suggests that axin’s expression and
spatial regulation is a dynamic process. Despite increasing knowledge on glioma biology and genetics, the prognostic
tools for glioblastoma still need improvement. Our findings on expression of axin 1 may contribute to better understand-
ing of glioblastoma molecular profile.
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Introduction
Our study analyzed the brain tumor glioblastoma,
with regard to the role of the tumor suppressor protein –
axin 1, a critical component of wnt signaling pathway.
AXIN-1 gene, located at 16p13.3, consists of 10 exons, en-
codes a 96 kDa protein, and is an inhibitor of wnt signal-
ing. The so called classical canonical wnt pathway, medi-
ated through beta-catenin, plays an essential role in
development of many cancers1 and lately this pathway
has been implicated in brain tumorigenesis as well2–7.
New knowledge on wnt signaling shows that wnt pro-
teins and other components of the wnt signaling cascade,
namely beta-catenin and axin, regulate critical develop-
mental processes of normal CNS development8–11. Molec-
ular components of wnt signaling perform important
functions in CNS tissues.
Axin 1 is a key negative regulator of the Wnt signaling
pathway12. It down-regulates beta-catenin, wnt path-
way’s main effector signaling molecule, by facilitating its
phosphorylation by GSK3-beta1. It binds directly to APC
(adenomatous polyposis coli), beta-catenin, GSK3-beta
and dishevelled forming a so called »beta-catenin destruc-
tion complex« in which phosphorylated beta-catenin is
targeted for quick ubiquitinilation and degradation in
the 26S proteosome1,13. In response to wnt signaling, or
under the circumstances of mutated axin or APC, beta-
catenin is stabilized, accumulates in the cytoplasm and
enters the nucleus, where it finds a partner, a member of
the DNA binding protein family LEF/TCF. Together they
stimulate the expression of target genes including c-myc,
c-jun, fra-1 and cyclin D114–16.
101
Received for publication June 01, 2009
The etiology and pathogenesis of the tumors of the
central nervous system are still inadequately explained.
Our knowledge on genetic background of specific histo-
pathological type of brain tumor still needs to be eluci-
dated although great progress has been achieved along
with the increasing advances in molecular genetics. Glio-
blastoma is the most aggressive form of glial brain tumor.
The majority of glioblastomas arise without clinical or
histological evidence of less malignant lesion and this
kind of glioblastoma is categorized as primary or de novo
glioblastoma. They manifest in older patients (mean age
55 years) after a short clinical history. In contrast, sec-
ondary glioblastomas develop more slowly by malignant
progression from diffuse or anaplastic astrocytoma and
they manifest in younger patients (mean age 40 years)17,18.
At present specific genetic alterations found to be associ-
ated with glioblastoma are emerging19–21. Nevertheless,
the genetic basis of primary as well as reoccurring glio-
blastoma is unclear, and much work is still required to
determine the final list of genes involved.
In this study we offer a new candidate, axin 1, to fill in
the puzzle of genetic basis of glioblastoma. Novel genes
and molecular candidates involved in mechanisms of
brain tumor formation will offer improvement in com-
prehension, diagnosis and treatment of this disease.
Materials and Methods
Tumor specimen
Samples of 42 glioblastomas were collected from the
Department of Neurosurgery, and Department of Pathol-
ogy Ljudevit Jurak at the »Sestre milosrdnice« Univer-
sity Hospital, Zagreb, Croatia. Using magnetic resonance
imaging (MRI), tumor lesions were found in different ce-
rebral regions (predominantly in the temporal and pari-
etal region), with the surrounding zone of perifocal oe-
dema. During surgery, the tumor was removed using a
microneurosurgical technique. The patients had no fam-
ily history of brain tumors, nor had they undergone che-
motherapy or radiotherapy prior to surgery. All tumors
were studied by pathologists and classified according to
the WHO criteria. Majority as primary glioblastomas be-
cause the diagnosis of glioblastoma was made at the first
biopsy, without clinical or histopathologic evidence of a
less malignant precursor lesion, while five samples were
classified as secondary since they developed from previ-
ously diagnosed tumors of lower malignancy grade.
There were 54.76% of male, and 45.24% of female pa-
tients. Patient age ranged from 31 to 80. The mean age at
diagnosis was 59.9 years.
The local Ethical Committee approved our study, and
patients gave their informed consent.
Immunohistochemistry
Immunohistochemistry was performed in order to es-
tablish the level of axin protein expression. The samples
were formalin-fixed, paraffin-embedded, and 4-mm thick
sections were placed on Capillary gap microscope slides
(DakoCytomation, Denmark). The sections were immuno-
stained using the peroxidase-anti-peroxidase method. De-
paraffinized and rehydrated sections were microwaved
in Dako Target Retrieval Solution (Dako Corporation,
USA) three times for 5 min at 800 W to unmask epitopes.
To block endogenous peroxidase activity, we fixed the
cells in methanol containing 3% H2O2. Non-specific bind-
ing was blocked by the application of normal mouse or
rabbit serum for 30 min in a humid chamber. Slides were
blotted and the primary antibodies at optimized dilu-
tions of 1:100 for axin were applied for 30 min at room
temperature22. The antibodies used were rabbit polyclo-
nal anti-human AXIN1 antibody (Zymed Laboratories,
San Francisco, CA, USA). After incubation, the slides
were washed three times in phosphate-buffered saline/goat
serum. Secondary LINK antibody was applied for 25
min. The washing was repeated, and the slides were in-
cubated with streptavidin horseradish peroxidase for an-
other 25 min. All chemicals were from DakoCytomation.
Negative controls were samples that underwent same
staining procedure with the exclusion of the primary an-
tibodies. Cortex of the frontal part of the normal brain,
as well as normal skin, served as positive controls. The
analysis of the labeling was performed by two independ-
ent observers, pathologists experts in the field blinded to
the conditions of the experiment, on an Olympus BH-2
microscope. Weak expression was labeled as +, moderate
expression as ++, and strong expression as +++.
Image analysis
Protein expression was then quantified with the aid of
Image Analyzer. For each sample, the intensity of stain-
ing in a well-defined area was evaluated using image-an-
alyzing software manufactured by Vamstec (Zagreb, Croa-
tia). The area covered by microscopic assessment was
200,000 square micrometers (200,000 mm2), i.e. approxi-
mately area 0.447x0.447 mm, with magnification x100.
The chosen area was located in the central part of the ex-
cised tissue containing most characteristics of malignant
tissue. All density measurements were »calibrated« against
its slide characteristics, i.e. transparency. Density was
depicted as the intensity of light retained by tissue or tis-
sue transparency and expressed in grey scale pixels rang-
ing from 0 to 222 for axin protein, zero representing no
transmission of light and 222 total transparency. Density
in the area of tumor location was compared with density
of the normal brain tissue sections.
Statistical methods
All individuals were analyzed for the following fea-
tures: PHD status, sex, age, AXIN1 protein expression
and localization. The Kolmogorov-Smirnov statistics tests
the hypothesis that the data are normally distributed. A
low significant value (less than 0.05) indicates that the
distribution of the data differs significantly from a nor-
mal distribution. If there are less than 50 cases the
Shapiro-Wilk test is also used with the same provision. In
our case the significance was p=0.221 indicating that the
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distribution was sufficiently normal to use the Pearson’s
correlation test.
Differences in the frequencies of the analyzed fea-
tures were tested with the T-student test and Pearson’s
correlation when appropriate.
Results
From 42 glioblastoma samples 88.1% appeared to
have developed de novo, while five samples developed
from previously diagnosed tumors of lower malignancy
grade, one from diffuse astrocytoma (GII), one from ana-
plastic astrocytoma (GIII), two from oligoastrocytoma
and one from oligodendroglioma. The histopathological
diagnosis of glioblastoma (malignancy grade IV) was
based on recognition of poorly differentiated astrocytic
tumor cells with brisk mytotic activity and marked nu-
clear atypia. Differentiated elements were intermingled
with bizarre multinucleated tumor giant cells. Promi-
nent microvascular hyperplasia, in which proliferating
blood vessels come to be lined by cells heaped up in disor-
derly fashion and transformed into glomeruloid or solid
tufts, and necrosis were also recognized as diagnostic fea-
tures.
The examination of axin’s expression levels demon-
strated samples with lower but also samples with higher
expression than observed in normal brain tissue. The ex-
pression of axin in the sections of normal brain white
matter, in which we analyzed microglia (astocytes and
oligodendrocytes), was observed in the cytoplasm and la-
beled as moderate expression ++. Of 42 glioblastoma
31% had downregulation of this tumor suppressor gene
expression when compared to the levels of axin in healthy
brain tissues. Part of our investigated sample showed
lower levels of axin expression, but, on the other hand, in
38.1% of the sample (16/42) higher levels were observed.
The expression levels were evenly distributed in both fe-
males and males, and there was no correlation to any age
group.
Immunostaining also revealed localization of axin pro-
teins (Figure 1). The majority of glioblastomas (69.04%
of samples) had axin localized in the cytoplasm. Axin was
observed in both the cytoplasm and nucleus in 21.42% of
glioblastoma samples and 9.52% of glioblastomas had
axin expressed solely in the nucleus (Figure 2 A, B).
The pathohistological grade of the glioblastomas ana-
lyzed, the results of staining intensities and the localiza-
tions of proteins are shown in Table 1.
The obtained results were then evaluated by image
analysis as staining density, i.e. light permeability (LP).
Density was depicted as the intensity of light retained by
tissue or tissue transparency, and expressed in grey scale
pixels and it is reversely proportional to the protein
quantities. The results of immunostaining obtained by
three independent observers and by image analysis were
compatible and the correlation was very strong at the
p=0.003 level.
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Fig. 1. Axin protein distribution in glioblastomas according to
localization.
Fig. 2. Glioblastoma samples immunohistochemically stained for
protein expression of axin. (A) Cytoplasmic localization of axin
and (B) nuclear localization of axin.
A
B
Mean values for light permeabilities for axin in nor-
mal brain tissue was 63±15. These numbers enabled us
to calculate relative quantities of axin proteins in tumor
tissue. We introduced variable relative increase of pro-
tein expression in tumor tissue defined with following
equations: Axinrela=axinpro/axinnv x100. Axinrela rep-
resented relative increase or decrease of LP in tumor tis-
sue for axin; axinpro denoted measured LP in tumor tis-
sue; axinnvmean values of LP for axin in normal tissue.
We observed that higher relative levels of axin protein
are much more frequent when the distribution of axin
was in the nucleus. Also, when relative levels of axin are
low the protein is rarely distributed in the nucleus; it is
than mainly located in the cytoplasm. This trend, al-
though not statistically relevant, is also reflected on the
mean values of relative axin quantities in relation to per-
cent of subcellular axin’s localization. Mean values of rel-
ative axin’s expression obtained by image analysis showed
that the highest relative quantity of axin was measured
when the protein was in the nucleus and the lowest rela-
tive quantity of axin when the protein was localized in
the cytoplasm (Table 2). In our analyzed sample we did
not observe axin 1 protein expression differences between
de novo and secondary glioblastomas.
Discussion and Conclusion
The mechanisms of brain tumor initiation and pro-
gression have not yet been completely investigated and
elucidated. As with other tumors, the formation of brain
tumors is the result of multiple consecutive genetic chan-
ges that represent a critical factor in tumor evolution. No
consistent genetic abnormalities have been detected that
would indicate the genetic profile of glioblastoma20,23.
Histopathologically, an unambiguous distinction of glioma
subtypes has remained elusive, but they clearly evolve
through different genetic pathways. It also remains to be
shown whether these subtypes differ significantly with
respect to the molecular genetic alterations underlying
the oncogenesis and progression of glioblastoma. In case
of glioblastomas, little is known of genetic alterations of
molecules which contribute to activating Wnt signaling
pathways. Processes that include cellular adhesion, syn-
aptic rearrangements, embryonic cell patterning, prolif-
eration, differentiation, and apoptosis require the ex-
pression of molecular components of the wnt pathway.
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TABLE 2
COMPARISON OF RELATIVE VALUES FOR AXIN TO CELLULAR
LOCALIZATION
Cellular localization Axinrela*
Cytoplasm 172.3
Nucleus and cytoplasm 164.1
Nucleus 142.0
* Axinrela=axinpro/axinnv x100; Axinrela represented relative
increase or decrease of LP in tumor tissue for axin; axinpro de-
noted measured LP in tumor tissue; axinnv mean values of LP
for axin in normal tissue
TABLE 1
PATHOHISTOLOGICAL GRADE, EXPRESSION LEVELS AND
LOCALIZATIONS OF AXIN PROTEIN
Patient
no.
Diagnosis Axin protein
Localiza-
tion
Expres-
sion
11 Glioblastoma (IV) C +
2 Glioblastoma (IV) N +++
3 Glioblastoma (IV) C ++
4 Glioblastoma (IV) CN +++
5 Glioblastoma (IV) C ++
6 Glioblastoma (IV) CN +++
7 Glioblastoma (IV) C +++
8 Glioblastoma (IV) CN +++
9 Glioblastoma (IV) C +
10 Glioblastoma (IV) C +++
112 Glioblastoma (IV) C ++
122 Glioblastoma (IV) C +++
13 Glioblastoma (IV) C +++
14 Glioblastoma (IV) N +++
15 Glioblastoma (IV) C +++
16 Glioblastoma (IV) CN ++
17 Glioblastoma (IV) C ++
18 Glioblastoma (IV) C +
193 Glioblastoma (IV) C +
20 Glioblastoma (IV) CN ++
21 Glioblastoma (IV) C +
22 Glioblastoma (IV) C +++
23 Glioblastoma (IV) C ++
24 Glioblastoma (IV) C ++
25 Glioblastoma (IV) C +
264 Glioblastoma (IV) C +++
27 Glioblastoma (IV) N ++
28 Glioblastoma (IV) C ++
29 Glioblastoma (IV) CN +++
30 Glioblastoma (IV) C ++
31 Glioblastoma (IV) C +
32 Glioblastoma (IV) C +++
33 Glioblastoma (IV) CN +
34 Glioblastoma (IV) C +
35 Glioblastoma (IV) C +
36 Glioblastoma (IV) C +
37 Glioblastoma (IV) CN ++
38 Glioblastoma (IV) C +
39 Glioblastoma (IV) C +++
40 Glioblastoma (IV) CN +++
41 Glioblastoma (IV) N ++
42 Glioblastoma (IV) C +
+ = weak expression, ++ =moderate expression, +++= strong
expression; M=membranous; C= cytoplasmic; N = nuclear local-
ization.; 1from anaplastic astrocytoma (GIII); 2from oligoastrocy-
toma; 3from oligodendroglioma; 4from diffuse astrocytoma (GII)
Another negative regulator of wnt signaling, APC, shows
high expression in the CNS24, and is involved in initia-
tion of neuronal differentiation. With this in mind, we in-
vestigated a new candidate gene, tumor suppressor gene
axin 1, in a set of 42 glioblastomas.
Our first result on downregulation of this tumor sup-
pressor gene expression in 31% of glioblastoma samples
may indicate its involvement in tumorigenesis. When
wnt signaling functions properly upregulation of axin 1
leads to the phosphorylation and degradation of beta-
catenin13,14. In the subset of samples we analyzed this
degradation might be impaired because of low axin’s lev-
els which would lead to beta-catenin’s accumulation, sta-
bilization and activation of target genes.
Our investigated sample did not show only lower lev-
els of axin protein expression, but in 38.1% higher levels
were observed. It has been reported that physiological
concentrations of axin is low in Xenopus egg cells25. We
may speculate that the increase of axin which we observ-
ed may once again be the result of deregulation of wnt
signaling.
The subcellular location of axin is not well defined in
the literature. There are reports on axins levels and loca-
tions in Xenopus eggs25. It has also been shown that it is
located in cytoplasmic puncta26 in living mammalian
cells. Wang et al.27 report that axin 1 is highly co-local-
ized with beta-catenin in the cytoplasm of human cumu-
lus cells and that this localization denotes intact wnt sig-
naling. Our work shows for the first time the subcellular
location of axin in normal brain white matter and glio-
blastoma tissue. The majority of glioblastomas (69.04%)
had axin localized in the cytoplasm which is compatible
to other reports in normal tissues. Nevertheless, a not in-
substantial percent of samples had axin localized in the
nucleus.
Our results on axin’s different distribution regarding
cellular localization are not unusual. Distribution of axin
was reported previously by Anderson et al.28 Although
this group was studying distribution of proteins involved
in Wnt signaling in neoplastic colon, the obtained data on
the subcellular level are very similar to ours.
It is well known that axin is a scaffold protein that
can shuttle between the cytoplasm and the nucleus.
Nucleo-cytoplasmatic shuttling under normal circum-
stances suggests existence of possible »salvage pathway«
that would be activated by axin translocation to the nu-
cleus in order to reduce beta-catenin’ oncogenic activity
by exporting nuclear beta-catenin and degrading it in the
cytoplasm. Axin translocation to the nucleus and its in-
teraction with beta-catenin is required for axin induced
cytoplasmic shifting of beta-catenin12.
The product of the APC gene has a critical function in
the turnover of beta-catenin on the axin 1 scaffold pro-
tein, and lately it was shown16 that axin 1 activity in-
cludes facilitating c-myc degradation, as well. Our previ-
ous results on changes of APC tumor suppressor gene6,29
revealed the presence of gross deletions of APC gene in
60% of glioblastomas and 20% of astocytomas. One oligo-
astrocytoma and one medulloblastoma also showed LOH
of APC. Moreover, we also found two glioblastomas with
heteroduplexes indicating potential mutations in beta-
catenin’s exon 3.
Interesting results were obtained by image analysis
on axins’ levels and locations. Mean values of relative
axin’s expression obtained by image analysis showed that
the highest relative quantity of axin was measured when
the protein was in the nucleus and the lowest relative
quantity of axin when the protein was localized in the cy-
toplasm. This finding is also indicative of axin’s nucleo-
cytoplasmatic shuttling and is in accordance to literature
sources on low levels of cytoplasmic axin in normal phys-
iological circumstances. Our study explored axin’s exis-
tence at the subcellular level in glioblastomas and it sug-
gests that axin’s expression and spatial regulation is a
dynamic process.
In conclusion we believe that wnt signaling is impli-
cated in development of gliomas. Our findings on chan-
ges of protein expression of molecular component of wnt
signaling - axin 1, may contribute to better understand-
ing of human glial tumor molecular profile.
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IZRA@ENOST I SMJE[TAJ PROTEINA AKSINA U GLIOBLASTOMIMA
S A @ E T A K
Etiologija i patogeneza tumora sredi{njeg `iv~anog sustava jo{ uvijek je nedovoljno razja{njena. U ovoj studiji istra-
`ivani su obrasci ekspresije proteina aksina, izuzetno va`ne molekularne komponente signalnog puta Wnt, u 42 uzorka
glioblastoma ~ovjeka. Imunohistokemijskom metodom i image analizom utvr|ena je ja~ina ekspresije i lokalizacija pro-
teina u stanicama. Smanjena ekspresija ovog tumor supresorskog proteina uo~ena je u 31% analiziranih tumora uspo-
redbom s razinom ekspresije aksina u normalnom tkivu mozga. U 69% glioblastoma aksin je prona|en u citoplazmi, u
21,4% u jezgri i citoplazmi, dok je u 9,5% glioblastoma lokalizacija bila isklju~ivo u jezgrama. Srednje vrijednosti relativne
ekspresije proteina aksina dobivene image analizom pokazuju da je najve}a relativna koli~ina aksina izmjerena kada je
protein lokaliziran u jezgri, a najmanja relativna koli~ina aksina kada je lokaliziran u citoplazmi. Rezultati istra`ivanja
aksina u glioblastomima na unutarstani~noj razini pokazuju da je izra`enost aksina i njegova prostorna regulacija vrlo
dinami~an proces. Unato~ produbljivanju spoznaja o biologiji i genetici glijalnih tumora, saznanja o prognosti~kim para-
metrima za glioblastom jo{ uvijek nisu dostatna. Na{i rezultati o razini izra`enosti proteina aksina zasigurno }e dopri-
nijeti boljem razumijevanju molekularnog profila glioblastoma, te ponuditi potencijalne prognosti~ke zna~ajke.
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